IL323504A - (s)- טיאנפטין ושימוש בו לטיפול בהפרעות ומצבים הקשורים לקולטן המופעל על ידי פרוקסיזום פרוליפרטור - Google Patents

(s)- טיאנפטין ושימוש בו לטיפול בהפרעות ומצבים הקשורים לקולטן המופעל על ידי פרוקסיזום פרוליפרטור

Info

Publication number
IL323504A
IL323504A IL323504A IL32350425A IL323504A IL 323504 A IL323504 A IL 323504A IL 323504 A IL323504 A IL 323504A IL 32350425 A IL32350425 A IL 32350425A IL 323504 A IL323504 A IL 323504A
Authority
IL
Israel
Prior art keywords
enantiomer
tianeptine
pharmaceutically acceptable
acceptable salt
zwitterion
Prior art date
Application number
IL323504A
Other languages
English (en)
Inventor
Bruce Daugherty
Siobhan J Fogarty
Herbert W Harris
David Tai Hsu
Darryl C Rideout
Gregory M Sullivan
Seth Lederman
Original Assignee
Tonix Pharma Ltd
Bruce Daugherty
Siobhan J Fogarty
Herbert W Harris
David Tai Hsu
Darryl C Rideout
Gregory M Sullivan
Seth Lederman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Ltd, Bruce Daugherty, Siobhan J Fogarty, Herbert W Harris, David Tai Hsu, Darryl C Rideout, Gregory M Sullivan, Seth Lederman filed Critical Tonix Pharma Ltd
Publication of IL323504A publication Critical patent/IL323504A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL323504A 2023-03-27 2025-09-21 (s)- טיאנפטין ושימוש בו לטיפול בהפרעות ומצבים הקשורים לקולטן המופעל על ידי פרוקסיזום פרוליפרטור IL323504A (he)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363454958P 2023-03-27 2023-03-27
US202363463299P 2023-05-01 2023-05-01
US202363466999P 2023-05-16 2023-05-16
US202363468221P 2023-05-22 2023-05-22
US202363528631P 2023-07-24 2023-07-24
PCT/US2024/021799 WO2024206520A1 (en) 2023-03-27 2024-03-27 (s)-tianeptine and use in treating disorders and conditions associated with peroxisome proliferator-activated receptor

Publications (1)

Publication Number Publication Date
IL323504A true IL323504A (he) 2025-11-01

Family

ID=90735436

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323504A IL323504A (he) 2023-03-27 2025-09-21 (s)- טיאנפטין ושימוש בו לטיפול בהפרעות ומצבים הקשורים לקולטן המופעל על ידי פרוקסיזום פרוליפרטור

Country Status (6)

Country Link
EP (1) EP4688761A1 (he)
JP (1) JP2026513236A (he)
CN (1) CN121335888A (he)
AU (1) AU2024245246A1 (he)
IL (1) IL323504A (he)
WO (1) WO2024206520A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026068775A1 (en) * 2024-09-27 2026-04-02 Tonix Pharma Limited (s)-tianeptine and use in treating post-concussive syndrome, nociplastic pain syndrome and chronic overlapping pain conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2716623B1 (fr) 1994-02-25 1996-08-23 Adir Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs.
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2747921B1 (fr) 1996-04-24 1998-10-30 Adir Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
SE0104326D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic heterocycles
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
US9314469B2 (en) * 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
GB201208315D0 (en) * 2012-05-11 2012-06-27 Numedicus Ltd Pharmaceutical methods and compositions
WO2014059279A2 (en) * 2012-10-13 2014-04-17 The University Of Toledo Materials and methods useful to treat neuroblastomas and pheochromocytomas
JP6557674B2 (ja) * 2014-03-12 2019-08-07 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 新規クラスのミュー−オピオイド受容体アゴニスト

Also Published As

Publication number Publication date
CN121335888A (zh) 2026-01-13
AU2024245246A1 (en) 2025-10-30
JP2026513236A (ja) 2026-04-23
EP4688761A1 (en) 2026-02-11
WO2024206520A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
CN109793725B (zh) 治疗忧郁症和神经性疼痛的药物组合物及其应用
IL323504A (he) (s)- טיאנפטין ושימוש בו לטיפול בהפרעות ומצבים הקשורים לקולטן המופעל על ידי פרוקסיזום פרוליפרטור
BR112020012629A2 (pt) estimulantes de sgc
AU2015207867A1 (en) Compounds and methods for the treatment of pain and other diseases
JP2018528205A (ja) レボドパ誘発性ジスキネジア療法のための脳透過性クロモンオキシム誘導体
CA2828831C (en) Compounds and methods for the treatment of pain and other disorders
JP2024509936A (ja) Ｕｓｐ３０阻害剤及びその使用
JP5575663B2 (ja) 置換された２−アミノ−３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
JP6430015B2 (ja) 新規クロモンオキシム誘導体、および代謝型グルタミン酸受容体のアロステリックモジュレーターとしてのそれの使用
WO2018132829A1 (en) Novel glutamate transporter activators and methods using same
WO2026068775A1 (en) (s)-tianeptine and use in treating post-concussive syndrome, nociplastic pain syndrome and chronic overlapping pain conditions
CA2887420C (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
Gao The development and evaluation of multi-target-directed ligands as cholinergic and amyloid β aggregation inhibitors for Alzheimer's disease